Lynchburg Journal of Medical Science

Lynchburg Journal of Medical Science


Intensive Care


Dr. T Colletti


ABSTRACT: Benzodiazepines (BZDs) remain the "gold standard" for the management of acute alcohol withdrawal syndrome (AWS). An evolving body of evidence suggests that adjuvant use of additional therapies can reduce costly Intensive Care Unit (ICU) utilization for those with severe alcohol withdrawal and improve patient outcomes. Adjuvant ketamine, phenobarbital, dexmedetomidine, and gabapentin are some of the identified off-label agents used to help mitigate the neurochemical storm brought about by the abrupt cessation of alcohol. Current clinical evidence supports that BZD monotherapy may be inadequate for those with severe alcohol withdrawal syndrome (SAWS), and that combination "cocktails", in conjunction with Cognitive Bias Modification Therapy (CBM) may be a preferred inpatient management strategy


Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.

Off-campus users can also use 'Off-campus Download' button above for access.